Search

Rosy Sheng Donn

from Saratoga, CA
Age ~70
Get Report
Also known as:
Rosy S Donn, Rosy S Dong, Rosy S Terry, Rosy R Sheng
Phone and address:
13263 Via Grande Dr, Saratoga, CA 95070
(408) 741-5846
Related to:
Kristina L Voegele, 40Stephanie Sheng, 44Alice S Voegele, 39Steve Ninchun Sheng, 77Lin Tung, 56Rounda Y Sheng, 72Cindy H Yuen, 74Jeffrey Sheng, 40Eric Donn, 35Wei L Lin, 57Kehsun Lin, 36Steve Sheng, 73Lily C Donn, 43Siyi T Donn, 72Yuchih R Yuen, 68Amy Sheng, 46
Connected to:
Adam R Donn, 43Anthony Donn, 98Chris A Donn, 45Daniela Donn, 32Elizabeth R Donn, 76Jane A Donn, 77Jeff A Donn, 71Lynn B Donn, 69Robert C Donn, 78Ronald Donn, 82

Rosy Donn Phones & Addresses

  • 13263 Via Grande Dr, Saratoga, CA 95070 (408) 741-5846
  • Cupertino, CA
  • Sunnyvale, CA
  • San Jose, CA
  • Albany, CA
  • 13263 Via Grande Dr, Saratoga, CA 95070

Emails

e***[email protected]

Publications

Us Patents

Sustained Release Intraocular Implants And Methods For Preventing Retinal Dysfunction

View page
US Patent:
8293210, Oct 23, 2012
Filed:
Oct 29, 2007
Appl. No.:
11/927615
Inventors:
Glenn T. Huang - Fremont CA, US
James Burke - Santa Ana CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Kai-Ming Zhang - Irvine CA, US
Ton Lin - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Rosy Sheng Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/498
A61P 27/16
US Classification:
424 91, 424428, 514249
Abstract:
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

Intraocular Implants And Methods For Improving Vision

View page
US Patent:
8293741, Oct 23, 2012
Filed:
Apr 29, 2005
Appl. No.:
11/119021
Inventors:
James A. Burke - Santa Ana CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Kai-Ming Zhang - Irvine CA, US
Ton Lin - Irvine CA, US
Glenn Huang - Fremont CA, US
Brittany A. Jackson - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Rosy S. Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/495
US Classification:
514249, 514912
Abstract:
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.

Sustained Release Intraocular Implants And Methods For Preventing Retinal Dysfunction

View page
US Patent:
8425929, Apr 23, 2013
Filed:
Apr 30, 2004
Appl. No.:
10/837143
Inventors:
Glenn T. Huang - Fremont CA, US
James Burke - Santa Ana CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Kai-Ming Zhang - Irvine CA, US
Ton Lin - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Rosy Sheng Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61F 2/02
US Classification:
424428
Abstract:
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

Sustained Release Intraocular Implants And Methods For Treating Ocular Vasculopathies

View page
US Patent:
8506986, Aug 13, 2013
Filed:
Jan 31, 2008
Appl. No.:
12/024014
Inventors:
Glenn T Huang - Fremont CA, US
Brittany Jackson - Huntington Beach CA, US
James A. Burke - Santa Ana CA, US
Ton Lin - Irvine CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Larry A. Wheeler - Irvine CA, US
Rosy Sheng Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/498
A61K 9/14
US Classification:
424428, 514912, 514249
Abstract:
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Sustained Release Intraocular Implants And Methods For Treating Ocular Vasculopathies

View page
US Patent:
8580292, Nov 12, 2013
Filed:
Jan 31, 2008
Appl. No.:
12/024017
Inventors:
Glenn T Huang - Fremont CA, US
Brittany Jackson - Huntington Beach CA, US
James A. Burke - Santa Ana CA, US
Ton Lin - Irvine CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Larry A. Wheeler - Irvine CA, US
Rosy Sheng Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61F 2/00
A61K 31/498
US Classification:
424428, 514249
Abstract:
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Sustained Release Intraocular Implants And Methods For Preventing Retinal Dysfunction

View page
US Patent:
8609144, Dec 17, 2013
Filed:
Jun 19, 2008
Appl. No.:
12/142083
Inventors:
James Burke - Santa Ana CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Orilla C. Werhner - Anaheim CA, US
Ton C. Lin - Irvine CA, US
Maria Escobar - Foothill Ranch CA, US
Glenn Huang - Fremont CA, US
Kai-Ming Zhang - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Rosy S. Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 9/00
A61K 31/498
A61P 27/02
US Classification:
424486, 424484, 514249
Abstract:
Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

Sustained Release Intraocular Implants And Methods For Treating Ocular Vasculopathies

View page
US Patent:
20050244463, Nov 3, 2005
Filed:
Apr 30, 2004
Appl. No.:
10/836911
Inventors:
Glenn Huang - Fremont CA, US
Brittany Jackson - Huntington Beach CA, US
James Burke - Santa Ana CA, US
Ton Lin - Irvine CA, US
Patrick Hughes - Aliso Viejo CA, US
Larry Wheeler - Irvine CA, US
Rosy Donn - Saratoga CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K031/498
US Classification:
424427000, 514249000
Abstract:
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Sustained Release Intraocular Implants And Methods For Preventing Retinal Dysfunction

View page
US Patent:
20050244506, Nov 3, 2005
Filed:
Apr 29, 2005
Appl. No.:
11/118519
Inventors:
James Burke - Santa Ana CA, US
Patrick Hughes - Aliso Viejo CA, US
Werhner Orilla - Anaheim CA, US
Ton Lin - Irvine CA, US
Maria Escobar - Foothill Ranch CA, US
Glenn Huang - Fremont CA, US
Kai-Ming Zhang - Irvine CA, US
Larry Wheeler - Irvine CA, US
Rosy Donn - Saratoga CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61K031/498
A61K009/14
US Classification:
424489000, 514249000
Abstract:
Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.
Control profile
Rosy Sheng Donn from Saratoga, CA, age ~70 Get Report